The stock of Theravance Biopharma Inc (NASDAQ:TBPH) is a huge mover today! About 287,406 shares traded hands. Theravance Biopharma Inc (NASDAQ:TBPH) has risen 59.87% since April 14, 2016 and is uptrending. It has outperformed by 55.18% the S&P500.
The move comes after 7 months negative chart setup for the $1.76B company. It was reported on Nov, 16 by Barchart.com. We have $31.96 PT which if reached, will make NASDAQ:TBPH worth $88.00M less.
Theravance Biopharma Inc (NASDAQ:TBPH) Ratings Coverage
Out of 6 analysts covering Theravance Biopharma (NASDAQ:TBPH), 5 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 83% are positive. Theravance Biopharma has been the topic of 7 analyst reports since August 12, 2015 according to StockzIntelligence Inc. The stock of Theravance Biopharma Inc (NASDAQ:TBPH) has “Neutral” rating given on Wednesday, August 12 by Robert W. Baird. The stock of Theravance Biopharma Inc (NASDAQ:TBPH) earned “Buy” rating by Evercore on Monday, August 29. The rating was initiated by Guggenheim with “Buy” on Monday, June 20. Piper Jaffray initiated the shares of TBPH in a report on Thursday, November 3 with “Overweight” rating. The firm has “Underperform” rating given on Wednesday, October 12 by Robert W. Baird. The rating was initiated by Leerink Swann with “Outperform” on Thursday, May 12.
According to Zacks Investment Research, “Theravance Biopharma, Inc. is a biopharmaceutical company. It is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including bacterial infections, central nervous system (CNS)/pain, respiratory disease, and gastrointestinal (GI) motility dysfunction. Theravance Biopharma, Inc. is based in George Town, Cayman Islands.”
Insitutional Activity: The institutional sentiment increased to 3.32 in 2016 Q2. Its up 1.98, from 1.34 in 2016Q1. The ratio increased, as 5 funds sold all Theravance Biopharma Inc shares owned while 14 reduced positions. 22 funds bought stakes while 41 increased positions. They now own 48.58 million shares or 135.18% more from 20.66 million shares in 2016Q1.
Goldman Sachs Gp holds 15,882 shares or 0% of its portfolio. Citigroup Inc accumulated 0% or 6,875 shares. Panagora Asset Mngmt holds 0.02% or 212,115 shares in its portfolio. Rhumbline Advisers last reported 34,022 shares in the company. Credit Suisse Ag last reported 0% of its portfolio in the stock. Chesapeake Prns Mgmt Communication Md has invested 1.17% of its portfolio in Theravance Biopharma Inc (NASDAQ:TBPH). Price T Rowe Assocs Inc Md owns 210,763 shares or 0% of their US portfolio. Vanguard Grp Inc Inc owns 2.45M shares or 0% of their US portfolio. Old West Investment Mngmt Lc has 0.71% invested in the company for 43,081 shares. Harvest Mgmt Ltd Llc owns 13,000 shares or 0.22% of their US portfolio. Morgan Stanley has 0% invested in the company for 32,797 shares. Ameritas Investment Inc has invested 0% of its portfolio in Theravance Biopharma Inc (NASDAQ:TBPH). Pictet Asset Mgmt Ltd holds 57,074 shares or 0.01% of its portfolio. Bogle Mgmt L P De has invested 0.18% of its portfolio in Theravance Biopharma Inc (NASDAQ:TBPH). Paloma Prtn Mgmt holds 11,238 shares or 0% of its portfolio.
Insider Transactions: Since August 18, 2016, the stock had 0 insider buys, and 3 selling transactions for $1.74 million net activity. Shafer Bradford J also sold $1.35 million worth of Theravance Biopharma Inc (NASDAQ:TBPH) shares. $125,703 worth of Theravance Biopharma Inc (NASDAQ:TBPH) shares were sold by HAUMANN BRETT K.
More notable recent Theravance Biopharma Inc (NASDAQ:TBPH) news were published by: Fool.com which released: “Why Theravance Biopharma Inc Shares Tumbled 19.5% Today” on October 27, 2016, also Prnewswire.com with their article: “Theravance Biopharma to Report Third Quarter 2016 Financial Results on …” published on November 01, 2016, Prnewswire.com published: “Theravance Biopharma, Inc. Reports Third Quarter 2016 Financial Results and …” on November 08, 2016. More interesting news about Theravance Biopharma Inc (NASDAQ:TBPH) were released by: Prnewswire.com and their article: “Theravance Biopharma Announces Proposed Public Offerings of $100 Million of …” published on October 26, 2016 as well as Prnewswire.com‘s news article titled: “Theravance Biopharma Presents Interim Data from Ongoing Telavancin …” with publication date: October 31, 2016.
TBPH Company Profile
Theravance Biopharma, Inc. (Theravance Biopharma) is a biopharmaceutical company. The Firm is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Firm operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. The Company’s commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease (COPD). The Company’s neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases, including acute and chronic heart failure, hypertension and chronic kidney diseases, such as diabetic nephropathy. Neprilysin (NEP) is an enzyme that degrades natriuretic peptides.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.